For more than two decades, JPT Peptide Technologies has supported the global scientific community with high-quality peptide solutions for infectious disease research, vaccine development, and immune monitoring.
A particular focus of our work lies in emerging, neglected, and tropical diseases — areas where rapid scientific response and reliable research tools are critical, yet often underserved.
JPT has played an important role in multiple major global health initiatives and outbreak responses.
JPT's peptide microarrays and cyclic peptides contributed to the analysis of one of the first successful HIV vaccine trials, RV144. In collaboration with the National Institutes of Health (NIH), JPT also enabled cost-effective access to hundreds of HIV peptides for researchers worldwide, supporting broad international HIV research efforts.
During the early stages of the COVID-19 pandemic, JPT was the first company worldwide to provide ready-to-use SARS-CoV-2 peptide pools for immune monitoring and vaccine development.
JPT's peptide pools were subsequently used in a large number of peer-reviewed publications and contributed to immunological studies supporting the development and characterization of many COVID-19 vaccines.
JPT has continuously expanded its infectious disease portfolio in response to emerging global health threats, including:
Our ability to rapidly design and manufacture peptide tools enables fast scientific response during outbreaks and emerging epidemics.
First recorded cases of Ebola (15 000 recorded deaths)
HIV/ AIDS pandemic (estimated 44 million deaths)
SARS epidemic (783 recorded deaths)
Swine flu epidemic (2 million estimated deaths)
MERS epidemic (935 recorded deaths)
ZIKA (~ 60 recorded deaths, birth defects)
COVID-19 pandemic (estimated 30 million deaths)
New Mpox variant (600 recorded deaths)
Current Ebola epidemic (estimated 220 deaths until now)
JPT offers more than 25 ready-to-use catalog products for infectious disease applications.
JPT is particularly committed to supporting research in neglected and emerging infectious diseases, including:
Fast development and manufacturing of peptide tools during emerging outbreaks.
More than 20 years of peptide manufacturing experience with huge production capabilities in Germany. We can produce more than 1 mio peptides per year!
JPT's products have supported thousands of immunology and infectious disease studies worldwide.
JPT believes that access to reliable, high-quality peptide technologies is essential for accelerating vaccine development, improving immune monitoring, and advancing research against neglected diseases worldwide.
We are actively seeking strategic collaborations and partnerships to further expand access to critical research tools for global infectious disease challenges.
Check our list of products, click and go.
Get a quote